Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 3 , Pages 323-333 , September 2009

PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation

  • Madaswamy S. Muthu, MPharm

      Affiliations

    • Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India
    • ,
  • Manoj K. Rawat, MPharm

      Affiliations

    • Department of Pharmaceutics, Institute of Technology, Banaras Hindu University, Varanasi, India
    • ,
  • Amit Mishra, MPharm

      Affiliations

    • Department of Pharmaceutics, Institute of Technology, Banaras Hindu University, Varanasi, India
    • ,
  • Sanjay Singh, PhD

      Affiliations

    • Department of Pharmaceutics, Institute of Technology, Banaras Hindu University, Varanasi, India
    • Corresponding Author InformationCorresponding author. Department of Pharmaceutics, Institute of Technology, Banaras Hindu University, Varanasi – 221005, India.

Received 9 May 2008 ,Accepted 24 December 2008.

References 

  1. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Trochilin V, Langer R. Biodegradable long circulating nanospheres. Science. 1994;263:1600–1603
  2. Labhasetwar V, Song C, Levy RJ. Nanoparticles drug delivery systems. Adv Drug Deliv Rev. 1997;24:63–85
  3. Sinha VR, Bansal K, Kaushik R, Kumria R, Trehan A. Poly-epsilon-caprolactone microspheres and nanospheres: an overview. Int J Pharm. 2004;278:1–23
  4. Allemann E, Gurny R, Doelker E. Drug-loaded nanoparticles—preparation methods and drug targeting issues. Eur J Pharm Biopharm. 1993;39:173–191
  5. Brannon-Peppas L. Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int J Pharm. 1995;116:1–9
  6. Mainardes RM, Evangelista RC. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm. 2005;290:137–144
  7. Esmaeili F, Hosseini-Nasr M, Rad-Malekshahi M, Samadi N, Atyabi F, Dinaryand R. Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles. Nanomedicine. 2007;3:161–167
  8. Ravi Kumar MN, Bakowsky U, Lehr CM. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials. 2004;25:1771–1777
  9. Ravivarapu HB, Burton K, DeLuca PP. Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres. Eur J Pharm Biopharm. 2000;50:263–270
  10. Sussman N. Choosing an atypical antipsychotic. Int Clin Psychopharmcol. 2002;17:S29–S33
  11. Grant S, Fitton A. Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs. 1994;48:253–273
  12. Adamou M, Hale AS. Extrapyramidal syndrome and long-acting injectable risperidone. Am J Psychiatry. 2004;161:756–757
  13. Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry. 1993;38:S80–S88
  14. Budavari S. In: 13th ed. The Merck index. Whitehouse Station, NJ: Merck and Co., Inc.; 2001;p. 1478
  15. Hardman G, Limbid LE, Gilman AG. In: 10th ed. The pharmacological basis of therapeutics. New York: McGraw-Hill; 2001;p. 279
  16. Rabin C, Liang Y, Ehrlichman RS, Budhian A, Metzger KL, Majewski-Tiedeken C, et al. In vitro and in vivo demonstration of risperidone implants in mice. Schizophr Res. 2008;98:66–78
  17. Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry. 2003;64:18–23
  18. Vasavan Nair NP, Suranyi-Cadotte B, Schwartz G, Thavundayil JX, Achim A, Lizondo E, et al. A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence. J Clin Psychopharmacol. 1986;6:30S–37S
  19. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug loaded polymeric nanoparticles. Nanomedicine. 2006;2:8–21
  20. Schmolka IR. Artificial skin I. Preparation and properties of pluronic F-127 gels for treatment of burns. J Biomed Mater Res. 1972;6:571–582
  21. Barichello JM, Morishita M, Takayama K, Nagai T. Absorption of insulin from Pluronic F-127 gels following subcutaneous administration in rats. Int J Pharm. 1999;184:189–198
  22. Muthu MS, Singh S. Studies on biodegradable polymeric nanoparticles of risperidone: in vitro and in vivo evaluation. Nanomedicine. 2008;3:305–319
  23. Fessi H, Puisieux F, Devissaguet JP, inventors; xxxxxx, assignee.<7> Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles. United States patent US 5,118,528. 1992.
  24. Zili Z, Sfar S, Fessi H. Preparation and characterization of poly-epsilon-caprolactone nanoparticles containing griseofulvin. Int J Pharm. 2005;294:261–267
  25. Chorny M, Fishbein I, Danenberg HD, Golomb G. Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J Control Release. 2002;83:389–400
  26. Singh S, Muthu MS. Preparation and characterization of nanoparticles containing an atypical antipsychotic agent. Nanomedicine. 2007;2:233–240
  27. Verger ML, Fluckiger L, Kim Y, Hoffman M, Maincent P. Preparation and characterization of nanoparticles containing an antihypertensive agent. Eur J Pharm Biopharm. 1998;46:137–143
  28. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release. 1999;59:299–307
  29. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther. 2003;305:625–631
  30. Naiker DV, Catts SV, Catts VS, Bedi KS, Bryan-Lluka LJ. Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. Eur J Pharmacol. 2006;540:87–90
  31. Fray PJ, Sahakian BJ, Robbins TW, Koob GF, Iversen SD. An observational method for quantifying the behavioural effects of dopamine agonists: contrasting effects of d-amphetamine and apomorphine. Psychopharmacology. 1980;69:253–259
  32. Waddington JL. Psychopharmacological studies in rodents: stereotaxic intracerebral injections and behavioral assessment. In:  Joseph MH,  Waddington JL editor. Working methods in neuropharmacology. Manchester, UK: Manchester University Press; 1986;p. 1
  33. Betancourt T, Brown B, Brannon-Peppas L. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine. 2007;2:219–232
  34. Shenoy DB, Amiji MM. Poly (ethylene oxide)-modified poly (epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm. 2005;293:261–270
  35. Govender T, Riley T, Ehtezazi T, Garnett MC, Stolnik S, Illum L, et al. Defining the drug incorporation properties of PLA-PEG nanoparticles. Int J Pharm. 2000;199:95–110
  36. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54:631–651
  37. Protais P, Costentin J, Schwartz JC. Climbing behaviour induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology. 1976;50:1–6
  38. Keegan D. Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug. Can J Psychiatry. 1994;39:S46–S52
  39. Kerwin RW. The new atypical antipsychotics: a lack of extrapyramidal side-effects and new routes in schizophrenia research. Br J Psychiatry. 1994;164:141–148
  40. Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P, Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm. 2008;358:285–291

 This research was supported by University Grant Commission, New Delhi, India in terms of a Senior Research Fellowship.

PII: S1549-9634(09)00003-3

doi: 10.1016/j.nano.2008.12.003

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 5, Issue 3 , Pages 323-333 , September 2009

Article Tools

* Image Usage & Resolution